Spritam is an antiepileptic drug owned by Aprecia Pharmaceuticals that contains levetiracetam as its active ingredient. It was first authorized for market use on 31 July, 2015.
The generic version of Spritam can potentially hit the market after 14 March, 2034. This is the expiration date of its last patent, which means it is the earliest possible date the generic could become available.
Spritam is used for the management of epilepsy. It's active ingredient, levetiracetam, contributes to its effectiveness by impacting the neurotransmitters in the brain that can cause seizures.
Spritam is protected by three patents with the last one expiring on 14 March, 2034. The patents relate to a rapid disperse dosage form containing levetiracetam. As a result, the earliest possible date for the release of generic Spritam is 14 March, 2034. Below are the details of the patent: